Lead Product(s) : Lactulose
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cadila Pharma Launches Cadilose for Constipation, Hepatic Encephalopathy
Details : Cadilose is an advanced Lactulose formulation designed to effectively manage constipation and hepatic encephalopathy (HE).
Product Name : Cadilose
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 25, 2025
Lead Product(s) : Lactulose
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bausch Health Announces Favorable Topline Results From Investigative Formulation of Rifaximin SSD IR
Details : In the study, the treatment arm evaluating 40 mg BID of rifaximin SSD IR plus standard of care therapy met its primary endpoint of time to resolution of OHE.
Product Name : Xifaxan
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 31, 2020
Lead Product(s) : Lactulose
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 12, 2018
Lead Product(s) : Lactulose
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lactulose
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Blood Glucose Response After Oral Intake of Lactulose in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 18, 2016
Lead Product(s) : Lactulose
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lactulose
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Virginia Mason Medical Center | Cumberland Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 26, 2012
Lead Product(s) : Lactulose
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Virginia Mason Medical Center | Cumberland Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lactulose
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Virginia Mason Medical Center | Cumberland Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Kristalose as Bowel Evacuant Prior to Colonoscopy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 08, 2010
Lead Product(s) : Lactulose
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Virginia Mason Medical Center | Cumberland Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
